PHIO · Phio Pharmaceuticals Corp. · Executive Compensation
$0.91
+0.02 (+1.78%)
At close · Oct 21
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“The Company has limited cash resources, has incurred recurring operating losses and negative cash flows from its operations since its inception and has not yet recognized any product revenues. These factors have previously raised doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 6, 2026
Market Cap
$10.36M
Shares
11.62M
Volume · Oct 21
517
Avg daily vol (3M)
140.98K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Robert J. Bitterman | President and Chief Executive Officer | $1,159,432 |
| Lisa Carson | Chief Financial Officer | $373,015 |
| Robert M. Infarinato | Former Vice President and Chief Financial Officer | $226,688 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Robert J. Bitterman | President and Chief Executive Officer | $387,019 |
| Robert M. Infarinato | Vice President and Chief Financial Officer | $105,206 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert J. Bitterman | President and Chief Executive Officer | $437,892 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Gerrit Dispersyn | Dr. Med. Sc. Former President and Chief Executive Officer | $489,769 |
| Robert J. Bitterman | President and Chief Executive Officer | $109,380 |
| Geert Cauwenbergh | Dr. Med. Sc. Former interim Principal Executive and Financial Officer | $77,362 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Gerrit Dispersyn | Dr. Med. Sc. Former President and Chief Executive Officer | $751,479 |
| Robert J. Bitterman | President and Chief Executive Officer | $78,300 |
| Geert Cauwenbergh | Dr. Med. Sc. Former interim Principal Executive and Financial Officer | $58,300 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Gerrit Dispersyn | Dr. Med. Sc. Former President and Chief Executive Officer, Director | $583,142 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Gerrit Dispersyn | Dr. Med. Sc. President and Chief Executive Officer | $659,382 |
| John Barrett | Former Chief Development Officer | $260,594 |
| Geert Cauwenbergh | Dr. Med. Sc. Former Chief Executive Officer | $131,806 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Geert Cauwenbergh | Dr. Med. Sc. Former Chief Executive Officer | $610,436 |
| Gerrit Dispersyn | Dr. Med. Sc. President and Chief Executive Officer | $424,956 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| R. Todd Plott, M.D. | Board of Directors | Appointed | 2026-07-21 |
| David Deming | Lead Independent Director | Appointed | 2025-10-31 |
| Robert Ferrara | Lead Independent Director | Resigned | 2025-10-31 |
| Robert Ferrara | director | Resigned | 2025-10-31 |
| Robert L. Ferrara | Director | Appointed | 2025-09-15 |
| David H. Deming | Director | Appointed | 2025-09-15 |
| Curtis A. Lockshin, Ph.D. | Director | Appointed | 2025-09-15 |
| Jonathan E. Freeman, Ph.D. | Director | Appointed | 2025-09-15 |
| Patricia A. Bradford | Director | Appointed | 2025-09-15 |
| Robert J. Bitterman | Director | Appointed | 2025-09-15 |
| Lisa Carson | VP, Finance and Administration | Appointed | 2025-06-12 |
| Robert Infarinato | VP, Strategic Development | Appointed | 2025-06-12 |
| Lisa Carson | principal financial officer and principal accounting officer | Appointed | 2025-06-12 |
| David H. Deming | Board of Directors | Appointed | 2025-02-20 |
| Robert M. Infarinato | principal accounting officer | Appointed | 2024-08-01 |
| Robert M. Infarinato | Vice President, Chief Financial Officer | Appointed | 2024-08-01 |
| Robert Bitterman | President and Chief Executive Officer | Appointed | 2023-02-22 |
| Robert J. Bitterman | Chair of the Board | Appointed | 2023-02-22 |
| Robert J. Bitterman | President and Chief Executive Officer | Appointed | 2023-02-22 |
| Robert J. Bitterman | interim Executive Chairman | Appointed | 2022-09-29 |
Leadership
- Geert Cauwenbergh CEO
- Geert Cauwenbergh, Dr. Med. Sc. CEO
- Gerrit Dispersyn CEO, Board Member
- Robert Bitterman CEO
- Robert J. Bitterman CEO, Chairman, Board Member
- Lisa Carson CFO
- Robert M. Infarinato CFO, Chief Accounting Officer
- Curtis A. Lockshin, Ph.D. Board Member
- David H. Deming Board Member
- Jonathan E. Freeman, Ph.D. Board Member
- Patricia A. Bradford Board Member
- R. Todd Plott, M.D. Board Member
- Robert L. Ferrara Board Member